Logo image of FBRX

FORTE BIOSCIENCES INC (FBRX) Stock Fundamental Analysis

NASDAQ:FBRX - Nasdaq - US34962G2084 - Common Stock - Currency: USD

11.32  +0.97 (+9.37%)

After market: 11.1 -0.22 (-1.94%)

Fundamental Rating

2

Overall FBRX gets a fundamental rating of 2 out of 10. We evaluated FBRX against 558 industry peers in the Biotechnology industry. While FBRX seems to be doing ok healthwise, there are quite some concerns on its profitability. FBRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year FBRX has reported negative net income.
In the past year FBRX has reported a negative cash flow from operations.
In the past 5 years FBRX always reported negative net income.
In the past 5 years FBRX always reported negative operating cash flow.
FBRX Yearly Net Income VS EBIT VS OCF VS FCFFBRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

FBRX's Return On Assets of -92.11% is on the low side compared to the rest of the industry. FBRX is outperformed by 74.19% of its industry peers.
FBRX's Return On Equity of -113.76% is in line compared to the rest of the industry. FBRX outperforms 42.65% of its industry peers.
Industry RankSector Rank
ROA -92.11%
ROE -113.76%
ROIC N/A
ROA(3y)-54.65%
ROA(5y)-93.03%
ROE(3y)-59.07%
ROE(5y)-168.83%
ROIC(3y)N/A
ROIC(5y)N/A
FBRX Yearly ROA, ROE, ROICFBRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FBRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FBRX Yearly Profit, Operating, Gross MarginsFBRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K

More info and screens

6

2. Health

2.1 Basic Checks

FBRX has more shares outstanding than it did 1 year ago.
FBRX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for FBRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FBRX Yearly Shares OutstandingFBRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
FBRX Yearly Total Debt VS Total AssetsFBRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

FBRX has an Altman-Z score of -2.64. This is a bad value and indicates that FBRX is not financially healthy and even has some risk of bankruptcy.
FBRX has a Altman-Z score (-2.64) which is comparable to the rest of the industry.
FBRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.64
ROIC/WACCN/A
WACCN/A
FBRX Yearly LT Debt VS Equity VS FCFFBRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 5.22 indicates that FBRX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.22, FBRX is in line with its industry, outperforming 54.66% of the companies in the same industry.
FBRX has a Quick Ratio of 5.22. This indicates that FBRX is financially healthy and has no problem in meeting its short term obligations.
FBRX has a Quick ratio of 5.22. This is comparable to the rest of the industry: FBRX outperforms 55.56% of its industry peers.
Industry RankSector Rank
Current Ratio 5.22
Quick Ratio 5.22
FBRX Yearly Current Assets VS Current LiabilitesFBRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for FBRX have decreased strongly by -61.96% in the last year.
EPS 1Y (TTM)-61.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.98% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.2%
EPS Next 2Y32.19%
EPS Next 3Y22.52%
EPS Next 5Y13.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FBRX Yearly Revenue VS EstimatesFBRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2029 2030 2031 2032 100M 200M 300M 400M
FBRX Yearly EPS VS EstimatesFBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

FBRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FBRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FBRX Price Earnings VS Forward Price EarningsFBRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBRX Per share dataFBRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as FBRX's earnings are expected to grow with 22.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.19%
EPS Next 3Y22.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FBRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORTE BIOSCIENCES INC

NASDAQ:FBRX (6/6/2025, 8:00:02 PM)

After market: 11.1 -0.22 (-1.94%)

11.32

+0.97 (+9.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-12 2025-08-12
Inst Owners73.43%
Inst Owner Change17.59%
Ins Owners1.96%
Ins Owner Change0.54%
Market Cap74.49M
Analysts82.22
Price Target60.18 (431.63%)
Short Float %2.42%
Short Ratio2.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.42%
Min EPS beat(2)-41.38%
Max EPS beat(2)26.55%
EPS beat(4)2
Avg EPS beat(4)-9.03%
Min EPS beat(4)-58.82%
Max EPS beat(4)37.53%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-60.67%
EPS NQ rev (1m)10.51%
EPS NQ rev (3m)28.54%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.94
P/tB 1.94
EV/EBITDA N/A
EPS(TTM)-15.11
EYN/A
EPS(NY)-3.74
Fwd EYN/A
FCF(TTM)-5.25
FCFYN/A
OCF(TTM)-5.23
OCFYN/A
SpS0
BVpS5.84
TBVpS5.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -92.11%
ROE -113.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.65%
ROA(5y)-93.03%
ROE(3y)-59.07%
ROE(5y)-168.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 213.95%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.22
Quick Ratio 5.22
Altman-Z -2.64
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.75%
EPS Next Y-11.2%
EPS Next 2Y32.19%
EPS Next 3Y22.52%
EPS Next 5Y13.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-135.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-135.36%
OCF growth 3YN/A
OCF growth 5YN/A